STOCK TITAN
  1. Home
  2. DNABW

Ginkgo Bioworks Holdings WTS (DNABW) Stock Price, News & Analysis

DNABW OTC
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
126 218 sessions, September 2, 2025 to September 2, 2026
Largest daily move
+266.7% close of June 18, 2026
1-year change
-98.7% closing prices, September 2, 2025 to September 2, 2026
1-month change
-75% closing prices, July 31, 2026 to September 2, 2026

Company Description

DNABW declined 98.7% in the 12 months to September 2, 2026. The last closing price was $0.0001.

For FY2025, Ginkgo Bioworks Holdings WTS reported revenue of $170.2M with net income of -$313K and diluted earnings per share of -$5.64. The company operates at a net profit margin of -0.2%.

This page collects what Stock Titan holds for DNABW, including price data, SEC filings, financial highlights, and short interest trends.

Stock Performance

Chart
$0.0001
No recent trading
Last close: September 2, 2026
-98.7%
1 year to September 2, 2026
-
Market Cap
-
Shares outstanding

Ginkgo Bioworks Holdings WTS (DNABW) closed at $0.0001 on September 2, 2026. In the 12 months to September 2, 2026, the price lost 98.7%.

See what a $1,000 investment in DNABW would be worth today

Average down calculator for DNABW

DNABW Metrics & Rankings

Revenue
$170.2M
#3,021
Piotroski F-Score
1/7 Partial
#7,860
September 2026
-50.0%
—
YTD
-98.0%
—

Price returns through September 2, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

View All

No recent news available for DNABW.

SEC Filings

View All

[144] Ginkgo Bioworks (DNA) officer may sell 2,200 shares

[4] Ginkgo Bioworks (NYSE: DNA) director sells 5,000 shares near $7.08

[144] Director plans potential 5,000-share sale at Ginkgo Bioworks (NYSE: DNA)

[4] Ginkgo Bioworks (DNA) CFO logs 743 RSU vesting, tax sale

[144] Ginkgo Bioworks (DNA) officer to sell 330 shares for taxes after vesting

[144] Ginkgo Bioworks (NYSE: DNA) insider plans 2,200-share sale

[10-Q] Biosecurity sale shapes Ginkgo Bioworks (NYSE: DNA) Q2 2026 results

[8-K] Ginkgo Bioworks (NYSE: DNA) posts Q2 loss, wins $47M lab deal

[4] Ginkgo Bioworks (NYSE: DNA) awards RSUs to 10% owner

[4] New RSU awards for Ginkgo Bioworks (NYSE: DNA) founder Reshma Shetty

Ginkgo Bioworks Holdings WTS has filed 10 recent SEC filings, including 4 Form 4, 4 Form 144, 1 Form 10-Q, 1 Form 8-K. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DNABW SEC filings →

Financial Highlights

View Full Financials

Ginkgo Bioworks Holdings WTS generated $170.2M in revenue in FY2025, operating income reached -$315.3M, and net income was -$313K, reflecting a -0.2% net profit margin. Diluted earnings per share stood at -$5.64. The company generated -$171.1M in operating cash flow. The current ratio was 4.92, measuring current assets divided by current liabilities.

$170.2M
Revenue (FY2025)
-$313K
Net Income (FY2025)
-$5.64
Diluted EPS (FY2025)
-$171.1M
Operating Cash Flow
-0.2%
Net Profit Margin
4.92
Current Ratio

Upcoming Events

No upcoming events scheduled for DNABW.

Short Interest History

Last 12 Months

Short interest in Ginkgo Bioworks Holdings WTS (DNABW) currently stands at 10.9 thousand shares.

Days to Cover History

Last 12 Months

Days to cover for Ginkgo Bioworks Holdings WTS (DNABW) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume.

Frequently Asked Questions

Ginkgo Bioworks Holdings WTS (DNABW) has no recent trading. Its last close was $0.0001 on September 2, 2026.

The FY2025 revenue of Ginkgo Bioworks Holdings WTS (DNABW) is $170.2M, from its most recent completed fiscal year.

The FY2025 net income of Ginkgo Bioworks Holdings WTS (DNABW) is -$313K, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Ginkgo Bioworks Holdings WTS (DNABW) is -$5.64 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Ginkgo Bioworks Holdings WTS (DNABW) is -$171.1M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Ginkgo Bioworks Holdings WTS (DNABW) is -0.2% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The current ratio of Ginkgo Bioworks Holdings WTS (DNABW), current assets divided by current liabilities, was 4.92 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Ginkgo Bioworks Holdings WTS (DNABW) is -$315.3M for FY2025, its most recent completed fiscal year. Learn about operating income.